Loading
Life sciences · Journal article
Microorganisms · October 23, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
The fungal microbiome is an increasingly recognized component of the tumor microenvironment, yet its interactions with cancer development and systemic anticancer therapy remain poorly characterized. This review summarizes current evidence on the role of fungi in tumors and their interactions with systemic chemotherapy and antifungal therapy. We discuss potential mechanisms by which the mycobiota may contribute to oncogenesis through immune modulation, remodeling of the tumor microenvironment, chronic inflammation, angiogenesis, and other tumor-supportive processes. We further examine evidence that several anticancer agents, including doxorubicin, cisplatin, and bleomycin, exhibit antifungal activity in vitro and may influence fungal growth, virulence-associated processes, and the selection of resistant fungal phenotypes. Conversely, fungal biofilm formation, hypoxia, and cellular stress-response mechanisms may affect susceptibility to antifungal and potentially anticancer agents. Particular attention is given to the poorly understood relationship between systemic chemotherapy and the gut mycobiome and its potential implications for intestinal dysbiosis and systemic complications. Overall, the complex and potentially bidirectional interactions between fungi, tumors, and systemic anticancer therapy warrant further investigation to determine their impact on treatment response and cancer outcomes, as well as their potential for therapeutic development.